GlobeNewswire: MYnd Analytics, Inc. Contains the last 10 of 101 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:05:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/07/18/1884744/0/en/Telemynd-Provides-Update-Following-Spinoff-Transaction-from-Emmaus-Life-Sciences-Formerly-MYnd-Analytics.html?f=22&fvtc=4&fvtv=15883Telemynd Provides Update Following Spinoff Transaction from Emmaus Life Sciences, Formerly MYnd Analytics2019-07-18T14:42:34Z<![CDATA[MISSION VIEJO, Calif. and TORRANCE Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Telemynd, Inc., a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today provide a business update following its spinoff from Emmaus Life Sciences, Inc. (“Emmaus”) (Nasdaq:EMMA), formerly MYnd Analytics, Inc.]]>https://www.globenewswire.com/news-release/2019/07/10/1880882/0/en/MYnd-Analytics-and-Emmaus-Life-Sciences-Stockholders-Approve-Merger-and-Spin-off-Transactions.html?f=22&fvtc=4&fvtv=15883MYnd Analytics and Emmaus Life Sciences Stockholders Approve Merger and Spin-off Transactions2019-07-10T13:20:00Z<![CDATA[MISSION VIEJO, Calif. and TORRANCE, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (Nasdaq: MYND), a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, announced that the proposed merger and spin-off transactions were approved by their respective stockholders (96% and 99.98%, respectively, of those shareholders voting) at the special stockholder meetings held yesterday, July 9, 2019.]]>https://www.globenewswire.com/news-release/2019/07/09/1880221/0/en/MYnd-Analytics-and-Emmaus-Life-Sciences-Report-Progress-on-Merger-and-Spin-off-Transaction.html?f=22&fvtc=4&fvtv=15883MYnd Analytics and Emmaus Life Sciences Report Progress on Merger and Spin-off Transaction2019-07-09T13:00:00Z<![CDATA[Merger and Spin-off Transaction on Track to Close by End of July]]>https://www.globenewswire.com/news-release/2019/06/12/1867720/0/en/MYnd-Analytics-and-Emmaus-Life-Sciences-Announce-Availability-of-Definitive-Joint-Proxy-Statement-Prospectus-Relating-to-Merger-and-Spin-off-Transaction.html?f=22&fvtc=4&fvtv=15883MYnd Analytics and Emmaus Life Sciences Announce Availability of Definitive Joint Proxy Statement/Prospectus Relating to Merger and Spin-off Transaction2019-06-12T14:56:26Z<![CDATA[MISSION VIEJO, Calif. and TORRANCE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (Nasdaq: MYND), a predictive analytics company aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, and Emmaus Life Sciences, Inc. (“Emmaus”), a leader in sickle cell disease treatment, announced today that the registration statement filed with the Securities and Exchange Commission (SEC), which includes the definitive joint proxy statement/prospectus of MYnd and Emmaus, was declared effective by the SEC on June 11, and companies intend to commence mailing to their stockholders on June 14. The respective special stockholder meetings will be held on July 9, 2019 to consider approval of the proposed merger and spin-off transaction announced in January of this year. The record date for each meeting is June 7, 2019.]]>https://www.globenewswire.com/news-release/2019/05/23/1841454/0/en/MYnd-Analytics-Announces-2-8-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=15883MYnd Analytics Announces $2.8 Million Registered Direct Offering2019-05-23T11:30:00Z<![CDATA[MISSION VIEJO, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering.]]>https://www.globenewswire.com/news-release/2019/05/20/1827833/0/en/Arcadian-Telepsychiatry-Signs-Agreement-with-Memorial-Hospital-at-Gulfport-to-Provide-Telehealth-Services.html?f=22&fvtc=4&fvtv=15883Arcadian Telepsychiatry Signs Agreement with Memorial Hospital at Gulfport to Provide Telehealth Services2019-05-20T13:15:00Z<![CDATA[GULFPORT, Miss., May 20, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that Arcadian Telepsychiatry, a wholly owned subsidiary of MYnd, has signed an agreement with Memorial to provide telebehavioral health services through its provider network beginning in May.]]>https://www.globenewswire.com/news-release/2019/05/13/1822554/0/en/MYnd-Analytics-Provides-Business-and-Merger-Updates.html?f=22&fvtc=4&fvtv=15883MYnd Analytics Provides Business and Merger Updates2019-05-13T13:15:00Z<![CDATA[Merger with Emmaus on Track to Close]]>https://www.globenewswire.com/news-release/2019/05/08/1819582/0/en/MYnd-Analytics-Partners-with-Care-Compass-Network-to-Offer-Telebehavioral-Health-Services.html?f=22&fvtc=4&fvtv=15883MYnd Analytics Partners with Care Compass Network to Offer Telebehavioral Health Services2019-05-08T15:15:00Z<![CDATA[MISSION VIEJO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has partnered with Care Compass Network (CCN), to offer telepsychiatry and teletherapy services, through Arcadian’s provider network.]]>https://www.globenewswire.com/news-release/2019/05/06/1817881/0/en/MYnd-Analytics-Interviewed-on-Bloomberg-International-on-the-RedChip-Money-Report.html?f=22&fvtc=4&fvtv=15883MYnd Analytics Interviewed on Bloomberg International on the RedChip Money Report2019-05-06T20:43:43Z<![CDATA[MISSION VIEJO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, aired on The RedChip Money Report television program. The interview aired Sunday, May 5, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa.]]>https://www.globenewswire.com/news-release/2019/04/17/1805509/0/en/MYnd-Analytics-Interview-to-Air-on-Bloomberg-International-on-the-RedChip-Money-Report.html?f=22&fvtc=4&fvtv=15883MYnd Analytics Interview to Air on Bloomberg International on the RedChip Money Report2019-04-17T13:20:00Z<![CDATA[MISSION VIEJO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a behavioral health company with tools and technologies aimed at improving the delivery of mental health services through the combination of telemedicine and data analytics, today announced an interview with its Chairman of the Board, Robin L. Smith, MD, MBA, will air on The RedChip Money Report television program. The interview will air Sunday, April 21, on Bloomberg International, available in 149 million homes across Europe, the Middle East, and Africa. Check local listings for times in your area.]]>